The United States Eventing Association (USEA) is excited to announce the renewed corporate partnership with longtime sponsor Adequan® i.m. (polysulfated glycosaminoglycan) as “The Official Joint Therapy Treatment of the USEA.” American Regent Animal Health, manufacturer of Adequan®, has increased its support of the USEA to be able to offer unparalleled prize money in the Advanced division at the 2019 USEA American Eventing Championships (AEC), which will be held at the iconic Kentucky Horse Park in Lexington, Kentucky, August 27 – September 1.
This year, in partnership with Adequan®, the USEA will host the new $60,000 Adequan® USEA® Advanced Final at the 2019 AEC, sending the Adequan® Champion home with a whopping $30,000 personalized check. The other $30,000 will be distributed as purse money through at least 8th place in the Adequan® USEA® Advanced Final.
“Our partners from Adequan® approached us asking whether increased investment would help to grow the Advanced Final at the American Eventing Championships and we were reminded once again of what an amazing supporter of the sport Adequan® is,” stated USEA CEO Rob Burk. “For over a decade, Adequan® has stepped up to support our horses and riders. Their investment will propel the $60,000 Adequan® USEA® Advanced Final forward as the most important upper level horse trial in the world! Coupled with the Kentucky Horse Park location, cross-country courses designed by the 2020 Olympic cross-country course designer Derek di Grazia, the same crew that runs the Land Rover Kentucky Three-Day Event (LRK3DE), and similar environmental conditions as will be experienced at the Tokyo Olympic Games, we believe this competition can be the jumping off point for North American based international riders on their path to the 2020 LRK3DE and the Olympic Games. The impact of this investment will be felt for years to come.”
Also new this year in conjunction with this partnership, the USEA has opened up the AEC Advanced qualifications to provide more opportunities nationwide to have a chance to compete in the final. Instead of qualifying for the final at 11 designated Gold Cup events, riders will now have over 30 opportunities to qualify at Advanced level and CCI events. To qualify for the $60,000 Adequan® USEA® Advanced Final at the AEC in 2019, competitors will need to complete a minimum of two events without cross-country jump penalties at any USEA Advanced recognized Horse Trials, a CCI4*-S (2018 CIC3*), a CCI4*-L (2018 CCI3*), a CCI5*-L (2018 CCI4*), or the FEI World Equestrian Games™. The qualifying period for the 2019 AEC is from May 28, 2018 through August 19, 2019.
“The discipline of eventing requires these amazing horses to be fit and sound to complete three days of intensive competition,” stated Allyn Mann, Director of Strategic Partnerships at American Regent Animal Health. “Advanced level horses and riders are being asked to test their skills every step of the way. We continue to show our appreciation to the owners and riders through our commitment to helping them support the health and well-being of these wonderful animals.”
Adequan® i.m. is indicated for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. Adequan® i.m. is the only FDA-approved PSGAG which has been proven to help improve joint function by reversing the disease cycle, repairing cartilage, restoring joint lubrication and reducing inflammation.[i],[ii] Ask your veterinarian if Adequan® i.m. is the right choice for your horse.
There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan. Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For more information and Full Prescribing Information, visit www.adequan.com.
The USEA is a non-profit 501(c)(3) educational organization committed to providing eventing enthusiasts with a competitive level suited to their individual skills. By assisting and educating competitors, event organizers, and officials; maintaining responsible safety standards; and registering qualified competitions and clinics, the USEA offers a strong and continuous training opportunity for an ever-expanding field of world-class competitors. Just as importantly, the USEA provides a means for all riders, regardless of age or ability, to experience the thrill of eventing. To learn more, visit www.useventing.com.
The USEA American Eventing Championships (AEC) is the pinnacle of the sport for the national levels. Held annually, the best junior, adult amateur, and professional competitors gather to vie for national championship titles at every level from Beginner Novice to Advanced. This ultimate test of horse and rider draws hundreds of horses and riders from around the country to compete for fabulous prizes, a piece of the substantial prize money, and the chance to be named the National Champion at their respective levels. The 2019 USEA American Eventing Championships will be held August 27-September 1, 2019 at the Kentucky Horse Park in Lexington, Kentucky. Click here to learn more about the USEA American Eventing Championships.
American Regent Animal Health, formerly known as Luitpold Animal Health, is a division of American Regent, Inc. American Regent Animal Health is committed to advancing animal health with proven FDA-approved products like Adequan®. The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for nearly three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified portfolio under the American Regent brand. For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 800-458-0163.
[i] Burba DJ, Collier MA, DeBault LE, Hanson-Painton O, Thompson HC, Holder CL: In vivo kinetic study on uptake and distribution of intramuscular tritium-labeled polysulfated glycosaminoglycan in equine body fluid compartments and articular cartilage in an osteochondral defect model. J Equine Vet Sci 1993; 13: 696-703.
[ii] Adequan® i.m. Package Insert, Rev 1/19.
PP-AI-US-0220 2/2019